PALOMA-3

A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Study Name:
A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The primary objective is to assess the pharmacokinetic noninferiority of amivantamab SC-CF via manual injection versus amivantamab IV.

Study Dates:
August 5, 2022 - August 1, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Janssen Research & Development, LLC

Sponsors:

Janssen Research & Development, LLC

Contact:

Phone: 1-844-434-4210
Email: [email protected]

ClinicalTrails.gov Identifier:
NCT05388669

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Community Connections - RSV: The Illness on Every Parent's Radar This Season
, | Feb 08, 2023